RXV Systems turns the prescriber signals life sciences already owns into forward, NPI-level valuation.
Reconcile the signals. Decode the prescriber. Value the opportunity.
The problem
You have an abundance without resolution problem.
What we found
Same data. Different meaning. Different value.
A claimed specialty is an administrative label, not a description of practice. An attributed prescription names one clinician, not everyone who shaped the decision. Two prescribers in the same decile can face entirely different access conditions. And the largest current writer is frequently the one with the least opportunity left.
Every one of those signals is correct on its own terms. None of them, alone, tells you what a prescriber is worth.
RXV Profile™
Illustrative profile and values
RXV models the forward opportunity. Current capture comes from your own booked sales. Headroom is the difference — which means the growth number is half yours.
Behind the profile sit observed clinical practice, relevant patient opportunity, treatment role, product access, prescribing activity and trajectory. What each contributes, and how they resolve into a dollar figure, is what we walk through in person.
Additive by design
Your data, your CRM, your field organization, your agencies. All of it stays. RXV sits above it and asks one question none of it was built to answer.
Your data is an input. Valuation is the output.
Life sciences has spent decades getting better at collecting signals around the prescriber. Those signals have rarely been carried the final step, into a forward economic view of what one prescriber’s opportunity is worth.
RXV doesn’t replace the data ecosystem. It resolves it.
The starting point
We’ll show you what it’s worth, what you’re capturing, what’s left, and where investment may need to change.